Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis

Published:2022-03 Issue:3 Volume:32 Page:185-194
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Gavriilaki Maria^ORCID,Moschou Maria,Papaliagkas Vasileios,Notas Konstantinos,Chatzikyriakou Evangelia,Zafeiridou Georgia,Papagiannopoulos Sotirios,Arnaoutoglou Marianthi^ORCID,Kimiskidis Vasilios K.

Publisher

Elsevier BV

Subject

Genetics (clinical),Neurology (clinical),Neurology,Pediatrics, Perinatology and Child Health

Reference62 articles.

1. Spinal muscular atrophy;Prior,1993

2. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function;Swoboda;Ann Neurol,2005

3. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications;Zerres;Arch Neurol,1995

4. Neurofilament as a potential biomarker for spinal muscular atrophy;Darras;Ann Clin Transl Neurol,2019

5. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study;Crawford;PLoS ONE,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis;Neurology and Therapy;2024-09-02

2. Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China;Brain and Behavior;2024-07

3. Insights into spinal muscular atrophy from molecular biomarkers;Neural Regeneration Research;2024-06-26

4. Stepping up for a practical biomarker of motor unit loss;Muscle & Nerve;2024-05-06

5. Neurophysiological Characteristics in Type II and Type III 5q Spinal Muscular Atrophy Patients: Impact of Nusinersen Treatment;Drug Design, Development and Therapy;2024-03